Driving Miss daisy............., page-11

Nothing moves quickly in biotech and there is one thing for certain - good assets are always good assets in the eyes of those who are looking for them. No doubt PTSD is a big thing at the moment (and could really change the SP if the trial results are very good). Oncology assets are valuable to those who are wanting to develop them. In my view, PTSD sits well in Bionomics and oncology doesn't, so I agree with the company's broader strategy. However, I don't see much SP movement until the 210 results come out. Anyway, the company has plenty of cash and it'll be able to look after itself for a while to come. GLTA